{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:32:51Z","timestamp":1791484371064,"version":"4.3.4"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s40263-017-0486-0","type":"journal-article","created":{"date-parts":[[2018,1,15]],"date-time":"2018-01-15T11:51:31Z","timestamp":1516017091000},"page":"33-45","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":102,"title":["Current Approaches and New Developments in the Pharmacological Management of Tourette Syndrome"],"prefix":"10.1007","volume":"32","author":[{"given":"Julio","family":"Quezada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A.","family":"Coffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,15]]},"reference":[{"issue":"2","key":"486_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.pediatrneurol.2012.05.002","volume":"47","author":"T Knight","year":"2012","unstructured":"Knight T, Steeves T, Day L, Lowerison M, Jette N, Pringsheim T. Prevalence of tic disorders: a systematic review and meta-analysis. Pediatr Neurol. 2012;47(2):77\u201390. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2012.05.002 .","journal-title":"Pediatr Neurol."},{"issue":"4","key":"486_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00787-011-0164-6","volume":"20","author":"DC Cath","year":"2011","unstructured":"Cath DC, Hedderly T, Ludolph AG, Stern JS, Murphy T, Hartmann A, Czernecki V, Robertson MM, Martino D, Munchau A, Rizzo R, ESSTS Guidelines Group. European clinical guidelines for Tourette syndrome and other tic disorders. Part I: assessment. Eur Child Adolesc Psychiatry. 2011;20(4):155\u201371.","journal-title":"Eur Child Adolesc Psychiatry."},{"issue":"8","key":"486_CR3","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1002\/mds.23053","volume":"25","author":"J Paszek","year":"2010","unstructured":"Paszek J, Pollok B, Biermann-Ruben K, M\u00fcller-Vahl K, Roessner V, Thomalla G, Robertson MM, Orth M, Schnitzler A, M\u00fcnchau A. Is it a tic?\u2014Twenty seconds to make a diagnosis. Mov Disord. 2010;25(8):1106\u20138.","journal-title":"Mov Disord."},{"key":"486_CR4","doi-asserted-by":"publisher","unstructured":"American Psychiatric Association. Neurodevelopmental disorders In: Diagnostic and statistical manual for mental disorders. 5th ed. American Psychiatric Publishing. https:\/\/doi.org\/10.1176\/appi.books.9780890425596.dsm01 . Accessed 6 Jul 2017.","DOI":"10.1176\/appi.books.9780890425596.dsm01"},{"issue":"19","key":"486_CR5","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1001\/jama.2010.607","volume":"303","author":"J Piacentini","year":"2010","unstructured":"Piacentini J, Woods DW, Scahill L, Wilhelm S, Peterson AL, Chang S, Ginsburg GS, Deckersbach T, Dziura J, Levi-Pearl S, Walkup JT. Behavior therapy for children with Tourette disorder: a randomized controlled trial. JAMA. 2010;303(19):1929\u201337.","journal-title":"JAMA."},{"issue":"3","key":"486_CR6","doi-asserted-by":"publisher","first-page":"16097","DOI":"10.1038\/nrdp.2016.97","volume":"2","author":"MM Robertson","year":"2017","unstructured":"Robertson MM, Eapen V, Singer HS, et al. Gilles de la Tourette syndrome. Nat Rev Dis Primers. 2017;2(3):16097.","journal-title":"Nat Rev Dis Primers."},{"issue":"11","key":"486_CR7","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1002\/mds.26414","volume":"30","author":"J Jankovic","year":"2015","unstructured":"Jankovic J. Therapeutic developments for tics and myoclonus. Mov Disord. 2015;30(11):1566\u201373.","journal-title":"Mov Disord."},{"key":"486_CR8","doi-asserted-by":"crossref","unstructured":"Hollis C, Pennant M, Cuenca J, Glazebrook C, Kendall T, Whittington C, Stockton S, Larsson L, Bunton P, Dobson S, Groom M, Hedderly T, Heyman I, Jackson GM, Jackson S, Murphy T, Rickards H, Robertson M, Stern J. Clinical effectiveness and patient perspectives of different treatment strategies for tics in children and adolescents with Tourette syndrome: a systematic review and qualitative analysis. Health Technol Assess. 2016;20(4):1\u2013450, vii\u2013viii.","DOI":"10.3310\/hta20040"},{"key":"486_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.neuropharm.2012.05.043","volume":"68","author":"V Roessner","year":"2013","unstructured":"Roessner V, Schoenefeld K, Buse J, Bender S, Ehrlich S, M\u00fcnchau A. Pharmacological treatment of tic disorders and Tourette syndrome. Neuropharmacology. 2013;68:143\u20139.","journal-title":"Neuropharmacology."},{"key":"486_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/B978-0-12-411546-0.00001-9","volume":"112","author":"D Martino","year":"2013","unstructured":"Martino D, Madhusudan N, Zis P, Cavanna AE. An introduction to the clinical phenomenology of Tourette syndrome. Int Rev Neurobiol. 2013;112:1\u201333.","journal-title":"Int Rev Neurobiol."},{"issue":"4","key":"486_CR11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00787-011-0163-7","volume":"20","author":"V Roessner","year":"2011","unstructured":"Roessner V, Plessen KJ, Rothenberger A, Ludolph AG, Rizzo R, Skov L, Strand G, Stern JS, Termine C, Hoekstra PJ, ESSTS Guidelines Group. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatry. 2011;20(4):173\u201396.","journal-title":"Eur Child Adolesc Psychiatry."},{"issue":"4","key":"486_CR12","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1212\/WNL.58.4.527","volume":"58","author":"Tourette\u2019s Syndrome Study Group","year":"2002","unstructured":"Tourette\u2019s Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology. 2002;58(4):527\u201336.","journal-title":"Neurology."},{"issue":"9","key":"486_CR13","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1080\/00048670802277222","volume":"42","author":"YS Du","year":"2008","unstructured":"Du YS, Li HF, Vance A, Zhong YQ, Jiao FY, Wang HM, Wang MJ, Su LY, Yu DL, Ma SW, Wu JB. Randomized double-blind multicentre placebo-controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders. Aust NZ J Psychiatry. 2008;42(9):807\u201313.","journal-title":"Aust NZ J Psychiatry."},{"issue":"3","key":"486_CR14","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1177\/070674371205700302","volume":"57","author":"T Pringsheim","year":"2012","unstructured":"Pringsheim T, Doja A, Gorman D, McKinlay D, Day L, Billinghurst L, Carroll A, Dion Y, Luscombe S, Steeves T, Sandor P. Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy. Can J Psychiatry. 2012;57(3):133\u201343.","journal-title":"Can J Psychiatry."},{"issue":"9","key":"486_CR15","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1097\/00004583-199509000-00010","volume":"34","author":"PB Chappell","year":"1995","unstructured":"Chappell PB, Riddle MA, Scahill L, Lynch KA, Schultz R, Arnsten A, Leckman JF, Cohen DJ. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette\u2019s syndrome: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry. 1995;34(9):1140\u20136.","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"issue":"Suppl 8","key":"486_CR16","first-page":"S156","volume":"88","author":"V Boon-yasidhi","year":"2005","unstructured":"Boon-yasidhi V, Kim YS, Scahill L. An open-label, prospective study of guanfacine in children with ADHD and tic disorders. J Med Assoc Thai. 2005;88(Suppl 8):S156\u201362.","journal-title":"J Med Assoc Thai."},{"issue":"7","key":"486_CR17","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1176\/appi.ajp.158.7.1067","volume":"158","author":"L Scahill","year":"2001","unstructured":"Scahill L, Chappell PB, Kim YS, Schultz RT, Katsovich L, Shepherd E, Arnsten AF, Cohen DJ, Leckman JF. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry. 2001;158(7):1067\u201374.","journal-title":"Am J Psychiatry."},{"issue":"6","key":"486_CR18","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/00002826-200211000-00009","volume":"25","author":"DD Cummings","year":"2002","unstructured":"Cummings DD, Singer HS, Krieger M, Miller TL, Mahone EM. Neuropsychiatric effects of guanfacine in children with mild Tourette syndrome: a pilot study. Clin Neuropharmacol. 2002;25(6):325\u201332.","journal-title":"Clin Neuropharmacol."},{"issue":"9","key":"486_CR19","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1089\/cap.2017.0024","volume":"27","author":"TK Murphy","year":"2017","unstructured":"Murphy TK, Fernandez TV, Coffey BJ, Rahman O, Gavaletz A, Hanks CE, Tillberg CS, Gomez LI, Sukhodolsky DG, Katsovich L, Scahill L. Extended-release guanfacine does not show a large effect on tic severity in children with chronic tic disorders. J Child Adolesc Psychopharmacol. 2017;27(9):762\u201370.","journal-title":"J Child Adolesc Psychopharmacol."},{"issue":"5","key":"486_CR20","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1177\/088307389901400508","volume":"14","author":"Y Awaad","year":"1999","unstructured":"Awaad Y. Tics in Tourette syndrome: new treatment options. J Child Neurol. 1999;14(5):316\u20139.","journal-title":"J Child Neurol."},{"issue":"5","key":"486_CR21","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1212\/WNL.56.5.599","volume":"56","author":"HS Singer","year":"2001","unstructured":"Singer HS, Wendlandt J, Krieger M, Giuliano J. Baclofen treatment in Tourette syndrome: a double-blind, placebo-controlled, crossover trial. Neurology. 2001;56(5):599\u2013604.","journal-title":"Neurology."},{"key":"486_CR22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1136\/jnnp.2009.185348","volume":"81","author":"J Jankovic","year":"2010","unstructured":"Jankovic J, Jimenez-Shahed J, Brown LW. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry. 2010;81:70\u20133.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"486_CR23","unstructured":"Highlights in prescribing information for Botox. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/103000s5232lbl.pdf , Accessed 16 Jul 2017."},{"key":"486_CR24","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1212\/WNL.56.5.605","volume":"56","author":"C Marras","year":"2001","unstructured":"Marras C, Andrews D, Sime E, Lang AE. Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. Neurology. 2001;56:605\u201310.","journal-title":"Neurology."},{"key":"486_CR25","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/NDT.S12990","volume":"8","author":"D Huys","year":"2012","unstructured":"Huys D, Hardenacke K, Poppe P, Bartsch C, Baskin B, Kuhn J. Update on the role of antipsychotics in the treatment of Tourette syndrome. Neuropsychiatr Dis Treat. 2012;8:95\u2013104.","journal-title":"Neuropsychiatr Dis Treat."},{"issue":"11","key":"486_CR26","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/s40265-014-0254-0","volume":"74","author":"CL Budman","year":"2014","unstructured":"Budman CL. The role of atypical antipsychotics for treatment of Tourette\u2019s syndrome: an overview. Drugs. 2014;74(11):1177\u201393.","journal-title":"Drugs."},{"issue":"2","key":"486_CR27","first-page":"CD006996","volume":"15","author":"T Pringsheim","year":"2009","unstructured":"Pringsheim T, Marras C. Pimozide for tics in Tourette\u2019s syndrome. Cochrane Database Syst Rev. 2009;15(2):CD006996.","journal-title":"Cochrane Database Syst Rev."},{"issue":"6","key":"486_CR28","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/s10072-011-0678-1","volume":"32","author":"M Gulisano","year":"2011","unstructured":"Gulisano M, Cal\u00ec PV, Cavanna AE, Eddy C, Rickards H, Rizzo R. Cardiovascular safety of aripiprazole and pimozide in young patients with Tourette syndrome. Neurol Sci. 2011;32(6):1213\u20137.","journal-title":"Neurol Sci."},{"issue":"8","key":"486_CR29","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1176\/ajp.154.8.1057","volume":"154","author":"FR Sallee","year":"1997","unstructured":"Sallee FR, Nesbitt L, Jackson C, Sine L, Sethuraman G. Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette\u2019s disorder. Am J Psychiatry. 1997;154(8):1057\u201362.","journal-title":"Am J Psychiatry."},{"issue":"6","key":"486_CR30","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1542\/peds.79.6.1032","volume":"79","author":"AK Shapiro","year":"1987","unstructured":"Shapiro AK, Shapiro E, Fulop G. Pimozide treatment of tic and Tourette disorders. Pediatrics. 1987;79(6):1032\u20139.","journal-title":"Pediatrics."},{"issue":"31 Pt 3","key":"486_CR31","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1177\/0957154X9700803109","volume":"8","author":"H Rickards","year":"1997","unstructured":"Rickards H, Hartley N, Robertson MM. Seignot\u2019s paper on the treatment of Tourette\u2019s syndrome with haloperidol. Hist Psychiatry. 1997;8(31 Pt 3):433\u20136.","journal-title":"Hist Psychiatry."},{"issue":"508","key":"486_CR32","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1192\/bjp.114.508.345","volume":"114","author":"AK Shapiro","year":"1968","unstructured":"Shapiro AK, Shapiro E. Treatment of Gilles De La Tourette\u2019s syndrome with haloperidol. Br J Psychiatry. 1968;114(508):345\u201350.","journal-title":"Br J Psychiatry."},{"issue":"8","key":"486_CR33","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/archpsyc.1989.01810080052006","volume":"46","author":"E Shapiro","year":"1989","unstructured":"Shapiro E, Shapiro AK, Fulop G, Hubbard M, Mandeli J, Nordlie J, Phillips RA. Controlled study of haloperidol, pimozide, and placebo for the treatment of Gilles De La Tourette\u2019s syndrome. Arch Gen Psychiatry. 1989;46(8):722\u201330.","journal-title":"Arch Gen Psychiatry."},{"issue":"5","key":"486_CR34","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1176\/ajp.135.5.585","volume":"135","author":"MS Ross","year":"1978","unstructured":"Ross MS, Moldofsky H. A Comparison of pimozide and haloperidol in the treatment of Gilles De La Tourette\u2019s syndrome. Am J Psychiatry. 1978;135(5):585\u20137.","journal-title":"Am J Psychiatry."},{"issue":"3","key":"486_CR35","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/00004714-199006000-00007","volume":"10","author":"P Sandor","year":"1990","unstructured":"Sandor P, Musisi S, Moldofsky H, Lang A. Tourette syndrome: a follow up study. J Clin Psychopharmacol. 1990;10(3):197\u20139.","journal-title":"J Clin Psychopharmacol."},{"issue":"1","key":"486_CR36","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1002\/mds.25692","volume":"29","author":"S Wijemanne","year":"2014","unstructured":"Wijemanne S, Wu LJ, Jankovic J. Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome. Mov Disord. 2014;29(1):126\u201330.","journal-title":"Mov Disord."},{"issue":"2","key":"486_CR37","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/0361-9230(83)90192-2","volume":"11","author":"RL Borison","year":"1983","unstructured":"Borison RL, Ang L, Hamilton WJ, Diamond BI, Davis JM. Treatment approaches in Gilles de la Tourette syndrome. Brain Res Bull. 1983;11(2):205\u20138.","journal-title":"Brain Res Bull."},{"issue":"4","key":"486_CR38","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ejpn.2011.12.001","volume":"16","author":"H Rickards","year":"2012","unstructured":"Rickards H, Cavanna AE, Worrall R. Treatment practices in Tourette syndrome: the European perspective. Eur J Paediatr Neurol. 2012;16(4):361\u20134.","journal-title":"Eur J Paediatr Neurol."},{"key":"486_CR39","doi-asserted-by":"publisher","first-page":"e772","DOI":"10.4088\/JCP.12m08189","volume":"74","author":"HK Yoo","year":"2013","unstructured":"Yoo HK, Joung YS, Lee JS, Song DH, Lee YS, Kim JW, Kim BN, Cho SC. A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette\u2019s disorder. J Clin Psychiatry. 2013;74:e772\u201380.","journal-title":"J Clin Psychiatry."},{"key":"486_CR40","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2016.0026","author":"F Sallee","year":"2017","unstructured":"Sallee F, Kohegyi E, Zhao J, McQuade R, Cox K, Sanchez R, van Beek A, Nyilas M, Carson W, Kurlan R. Randomized, double-blind, placebo-controlled trial demonstrates the efficacy and safety of oral aripiprazole for the treatment of Tourette\u2019s disorder in children and adolescents. J Child Adolesc Psychopharmacol. 2017. https:\/\/doi.org\/10.1089\/cap.2016.0026 .","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"486_CR41","unstructured":"Highlights of prescribing information for aripiprazole. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021436s038,021713s030,021729s022,021866s023lbl.pdf . Accessed 6 Jul 2017."},{"key":"486_CR42","doi-asserted-by":"publisher","first-page":"50","DOI":"10.4088\/JCP.v62n0111","volume":"62","author":"R Bruggeman","year":"2001","unstructured":"Bruggeman R, van der Linden C, Buitelaar C, Jan K, Gericke G, Hawkridge S, Temlett J. Risperidone versus pimozide in Tourette\u2019s disorder: a comparative double-blind parallel-group study. J Clin Psychiatry. 2001;62:50\u20136.","journal-title":"J Clin Psychiatry."},{"key":"486_CR43","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/00004583-200402000-00017","volume":"43","author":"D Gilbert","year":"2004","unstructured":"Gilbert D, Batterson J, Sethuramamn G, Sallee F. Tic reduction with risperidone versus pimozide in a randomized double-blind cross-over trial. J Am Acad Child Adolesc Psychiatry. 2004;43:206\u201314.","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"key":"486_CR44","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/00004714-200202000-00006","volume":"22","author":"Y Dion","year":"2002","unstructured":"Dion Y, Annable L, Sandor P, Couinard G. Risperidone in the treatment of Tourette syndrome: a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2002;22:31\u20139.","journal-title":"J Clin Psychopharmacol."},{"key":"486_CR45","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/00004583-200203000-00013","volume":"41","author":"G Gaffney","year":"2002","unstructured":"Gaffney G, Perry P, Lund B, Bever-Stille K, Arndt S, Kuperman S. Risperidone versus clonidine in the treatment of children and adolescents with Tourette\u2019s disorder. J Am Acad Child Adolesc Psychiatry. 2002;41:330\u20136.","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"key":"486_CR46","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1212\/01.WNL.0000055434.39968.67","volume":"60","author":"L Scahill","year":"2003","unstructured":"Scahill L, Leckman L, Schultz R, et al. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology. 2003;60:1130\u20135.","journal-title":"Neurology."},{"issue":"8","key":"486_CR47","doi-asserted-by":"publisher","first-page":"651","DOI":"10.2165\/11592020-000000000-00000","volume":"34","author":"T Pringsheim","year":"2011","unstructured":"Pringsheim T, Lam D, Ching H, et al. Metabolic and neurological complications of second generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials. Drug Saf. 2011;34(8):651\u201368.","journal-title":"Drug Saf."},{"issue":"1","key":"486_CR48","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/00004850-200015010-00003","volume":"15","author":"M Stamenkovic","year":"2000","unstructured":"Stamenkovic M, Schindler SD, Aschauer HN, et al. Effective open-label treatment of tourette\u2019s disorder with olanzapine. Int Clin Psychopharmacol. 2000;15(1):23\u20138.","journal-title":"Int Clin Psychopharmacol."},{"issue":"6","key":"486_CR49","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s004150070173","volume":"247","author":"M Onofrj","year":"2000","unstructured":"Onofrj M, Paci C, D\u2019Andreamatteo G, et al. Olanzapine in severe Gilles de la Tourette syndrome: a 52-week double-blind cross-over study vs low-dose pimozide. J Neurol. 2000;247(6):443\u20136.","journal-title":"J Neurol."},{"issue":"4","key":"486_CR50","doi-asserted-by":"publisher","first-page":"290","DOI":"10.4088\/JCP.v62n0412","volume":"62","author":"CL Budman","year":"2001","unstructured":"Budman CL, Gayer A, Lesser M, et al. An open-label study of the treatment efficacy of olanzapine for Tourette\u2019s disorder. J Clin Psychiatry. 2001;62(4):290\u20134.","journal-title":"J Clin Psychiatry."},{"issue":"2","key":"486_CR51","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1089\/1044546041648959","volume":"14","author":"RJ Stephens","year":"2004","unstructured":"Stephens RJ, Bassel C, Sandor P. Olanzapine in the treatment of aggression and tics in children with Tourette\u2019s syndrome\u2014a pilot study. J Child Adolesc Psychopharmacol. 2004;14(2):255\u201366.","journal-title":"J Child Adolesc Psychopharmacol."},{"issue":"5","key":"486_CR52","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1089\/cap.2007.135","volume":"18","author":"JT McCracken","year":"2008","unstructured":"McCracken JT, Suddath R, Chang S, et al. Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome. J Child Adolesc Psychopharmacol. 2008;18(5):501\u20138.","journal-title":"J Child Adolesc Psychopharmacol."},{"issue":"3","key":"486_CR53","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/00004583-200003000-00010","volume":"39","author":"FR Sallee","year":"2000","unstructured":"Sallee FR, Kurlan R, Goetz CG, Singer H, Scahill L, Law G, Dittman VM, Chappell PB. Ziprasidone treatment of children and adolescents with Tourette\u2019s syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry. 2000;39(3):292\u20139.","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"issue":"6","key":"486_CR54","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1097\/01.chi.0000215347.93902.3e","volume":"45","author":"FR Sallee","year":"2006","unstructured":"Sallee FR, Miceli JJ, Tensfeldt T, Robarge L, Wilner K, Patel NC. Single-dose pharmacokinetics and safety of ziprasidone in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2006;45(6):720\u20138.","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"issue":"7","key":"486_CR55","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.4088\/JCP.v68n0726e","volume":"68","author":"JL Jonge de","year":"2007","unstructured":"de Jonge JL, Cath DC, van Balkom AJ. Quetiapine in patients with Tourette\u2019s disorder. J Clin Psychiatry. 2007;68(7):1148\u201350.","journal-title":"J Clin Psychiatry."},{"issue":"3","key":"486_CR56","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1089\/104454603322572624","volume":"13","author":"NM Mukaddes","year":"2003","unstructured":"Mukaddes NM, Abali O. Quetiapine treatment of children and adolescents with Tourette\u2019s disorder. J Child Adolesc Psychopharmacol. 2003;13(3):295\u20139.","journal-title":"J Child Adolesc Psychopharmacol."},{"issue":"4","key":"486_CR57","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/BF00449911","volume":"237","author":"C Eggers","year":"1988","unstructured":"Eggers C, Rothenberger A, Berghaus U. Clinical and neurobiological findings in children suffering from tic disease following treatment with tiapride. Eur Arch Psychiatry Neurol Sci. 1988;237(4):223\u20139.","journal-title":"Eur Arch Psychiatry Neurol Sci."},{"issue":"10","key":"486_CR58","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/S0929-6646(09)60406-X","volume":"108","author":"CS Ho","year":"2009","unstructured":"Ho CS, Chen HJ, Chiu NC, Shen EY, Lue HC. Short-term sulpiride treatment of children and adolescents with Tourette syndrome or chronic tic disorder. J Formos Med Assoc. 2009;108(10):788\u201393.","journal-title":"J Formos Med Assoc."},{"key":"486_CR59","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/j.clinthera.2012.06.010","volume":"34","author":"JJ Chen","year":"2012","unstructured":"Chen JJ, Ondo WG, Dashtipour K, Swope DM. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Ther. 2012;34:1487\u2013504.","journal-title":"Clin Ther."},{"key":"486_CR60","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1212\/WNL.34.5.688","volume":"34","author":"J Jankovic","year":"1984","unstructured":"Jankovic J, Glaze DG, Frost JD Jr. Effect of tetrabenazine on tics and sleep of Gilles de la Tourette\u2019s syndrome. Neurology. 1984;34:688\u201392.","journal-title":"Neurology."},{"key":"486_CR61","doi-asserted-by":"crossref","first-page":"422","DOI":"10.5334\/tohm.287","volume":"6","author":"J Jankovic","year":"2016","unstructured":"Jankovic J, Jimenez-Shahed J, Budman C, Coffey B, Murphy T, Shprecher D, Stamler D. Deutetrabenazine in tics associated with Tourette syndrome. Tremor Other Hyperkinet Mov (NY). 2016;6:422 (eCollection 2016).","journal-title":"Tremor Other Hyperkinet Mov (NY)."},{"key":"486_CR62","unstructured":"Austedo medication package insert. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209885lbl.pdf . Accessed 22 Oct 2017."},{"key":"486_CR63","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s40265-017-0770-9","volume":"77","author":"ES Kim","year":"2017","unstructured":"Kim ES. Valbenazine: first global approval. Drugs. 2017;77:1123\u20139.","journal-title":"Drugs."},{"key":"486_CR64","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1055\/s-2002-25028","volume":"35","author":"KR M\u00fcller-Vahl","year":"2002","unstructured":"M\u00fcller-Vahl KR, Schneider U, Koblenz A, J\u00f6bges M, Kolbe H, Daldrup T, Emrich HM. Treatment of Tourette\u2019s syndrome with delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry. 2002;35:57\u201361.","journal-title":"Pharmacopsychiatry."},{"key":"486_CR65","doi-asserted-by":"publisher","first-page":"459","DOI":"10.4088\/JCP.v64n0417","volume":"64","author":"KR M\u00fcller-Vahl","year":"2003","unstructured":"M\u00fcller-Vahl KR, Schneider U, Prevedel H, Theloe K, Kolbe H, Daldrup T, Emrich HM. Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry. 2003;64:459\u201365.","journal-title":"J Clin Psychiatry."},{"key":"486_CR66","first-page":"CD006565","volume":"4","author":"A Curtis","year":"2009","unstructured":"Curtis A, Clarke CE, Rickards HE. Cannabinoids for Tourette\u2019s syndrome. Cochrane Database Syst Rev. 2009;4:CD006565.","journal-title":"Cochrane Database Syst Rev."},{"key":"486_CR67","first-page":"245","volume":"58","author":"CG Goetz","year":"1992","unstructured":"Goetz CG. Clonidine and clonazepam in Tourette syndrome. Adv Neurol. 1992;58:245\u201351.","journal-title":"Adv Neurol."},{"key":"486_CR68","first-page":"216","volume":"5","author":"I Drtilkova","year":"1996","unstructured":"Drtilkova I, Balastikova B, Lemanova H. Clonazepam, clonidine, and tiapride in children with tic disorder. Homeostasis. 1996;5:216.","journal-title":"Homeostasis."},{"issue":"4","key":"486_CR69","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/j.1600-0447.1985.tb02628.x","volume":"72","author":"JR Merikangas","year":"1985","unstructured":"Merikangas JR, Merikangas KR, Kopp U, Hanin I. Blood choline and response to clonazepam and haloperidol in Tourette\u2019s syndrome. Acta Psychiatr Scand. 1985;72(4):395\u20139.","journal-title":"Acta Psychiatr Scand."},{"key":"486_CR70","first-page":"255","volume":"35","author":"DE Comings","year":"1982","unstructured":"Comings DE, Gursey BT, Avelino E, Kopp U, Hanin I. Red blood cell choline in Tourette syndrome. Adv Neurol. 1982;35:255\u20138.","journal-title":"Adv Neurol."},{"issue":"1","key":"486_CR71","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1742-1241.1970.tb03263.x","volume":"24","author":"JA Frederiks","year":"1970","unstructured":"Frederiks JA. Facial tics in children: the therapeutic effect of low-dosage diazepam. Br J Clin Pract. 1970;24(1):17\u201320.","journal-title":"Br J Clin Pract."},{"issue":"1","key":"486_CR72","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/WNF.0000000000000017","volume":"37","author":"DL Gilbert","year":"2014","unstructured":"Gilbert DL, Budman CL, Singer HS, Kurlan R, Chipkin RE. A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome. Clin Neuropharmacol. 2014;37(1):26\u201330.","journal-title":"Clin Neuropharmacol."},{"key":"486_CR73","unstructured":"Gilbert D, Murphy T, Jankovic J, Budman C, Black K, Kurlan R, Coffman K, McCracken J, Juncos J, Grant J, Chipkin R. A randomized, double-blind, placebo-controlled study of the D1 receptor antagonist ecopipam for children and adolescents with Tourette syndrome [abstract]. Mov Disord. 2017;32(suppl 2). http:\/\/www.mdsabstracts.org\/abstract\/a-randomized-double-blind-placebo-controlled-study-of-the-d1-receptor-antagonist-ecopipam-for-children-and-adolescents-with-tourette-syndrome\/ . Accessed 3 Oct 2017."},{"key":"486_CR74","doi-asserted-by":"publisher","first-page":"7731","DOI":"10.1038\/srep07731","volume":"5","author":"F Zhang","year":"2015","unstructured":"Zhang F, Li A. Dual ameliorative effects of Ningdong granule on dopamine in rat models of Tourette\u2019s syndrome. Sci Rep. 2015;5:7731. https:\/\/doi.org\/10.1038\/srep07731 .","journal-title":"Sci Rep."},{"issue":"4","key":"486_CR75","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s11655-009-0261-2","volume":"15","author":"AY Li","year":"2009","unstructured":"Li AY, Cong S, Lu H, Li JJ, Zhao L. Clinical observation on treatment of Tourette syndrome by integrative medicine. Chin J Integr Med. 2009;15(4):261\u20135.","journal-title":"Chin J Integr Med."},{"issue":"1","key":"486_CR76","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1749-8546-9-6","volume":"9","author":"YH Kim","year":"2014","unstructured":"Kim YH, Son CG, Ku BC, Lee HW, Lim HS, Lee MS. Herbal medicines for treating tic disorders: a systematic review of randomised controlled trials. Chin Med. 2014;9(1):6.","journal-title":"Chin Med."},{"issue":"1","key":"486_CR77","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1177\/147323001003800119","volume":"38","author":"L Zhao","year":"2010","unstructured":"Zhao L, Li AY, Lv H, Liu FY, Qi FH. Traditional Chinese medicine Ningdong granule: the beneficial effects in Tourette\u2019s disorder. J Int Med Res. 2010;38(1):169\u201375.","journal-title":"J Int Med Res."},{"key":"486_CR78","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/jcpp.12432","volume":"57","author":"Y Zheng","year":"2016","unstructured":"Zheng Y, Zhang Z-J, Han X-M, Ding Y, Chen Y-Y, Wang X-F, Wei X-W, Wang M-J, Cheng Y, Nie Z-H, Zhao M, Zheng X-X. A proprietary herbal medicine (5-Ling Granule) for Tourette syndrome: a randomized controlled trial. J Child Psychol Psychiatr. 2016;57:74\u201383.","journal-title":"J Child Psychol Psychiatr"},{"issue":"6","key":"486_CR79","doi-asserted-by":"publisher","first-page":"e1493","DOI":"10.1542\/peds.2011-3384","volume":"129","author":"V Gabbay","year":"2012","unstructured":"Gabbay V, Babb JS, Klein RG, et al. A double-blind, placebo-controlled trial of omega-3 fatty acids in Tourette\u2019s disorder. Pediatrics. 2012;129(6):e1493\u2013500.","journal-title":"Pediatrics."},{"key":"486_CR80","doi-asserted-by":"publisher","first-page":"6389","DOI":"10.1523\/JNEUROSCI.1007-05.2005","volume":"25","author":"MM Moran","year":"2005","unstructured":"Moran MM, McFarland K, Melendez RI, Kalivas PW, Seamans JK. Cystine\/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. J Neurosci. 2005;25:6389\u201393.","journal-title":"J Neurosci"},{"issue":"4","key":"486_CR81","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1089\/cap.2015.0109","volume":"26","author":"MH Bloch","year":"2016","unstructured":"Bloch MH, Panza KE, Yaffa A, Alvarenga PG, Jakubovski E, Mulqueen JM, Landeros-Weisenberger A, Leckman JF. N-Acetylcysteine in the treatment of pediatric Tourette syndrome: randomized, double-blind, placebo-controlled add-on trial. J Child Adolesc Psychopharmacol. 2016;26(4):327\u201334.","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"486_CR82","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/mds.24919","volume":"27","author":"R Kurlan","year":"2012","unstructured":"Kurlan R, Crespi G, Coffey B, Mueller-Vahl K, Koval S, Wunderlich G, on behalf of the Pramipexole for TS Trial Investigators. A multicenter randomized placebo-controlled clinical trial of pramipexole for Tourette\u2019s syndrome. Mov Disord. 2012;27:775\u20138.","journal-title":"Mov Disord"},{"issue":"1","key":"486_CR83","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1089\/104454604773840562","volume":"14","author":"MT Acosta","year":"2004","unstructured":"Acosta MT, Castellanos FX. Use of the \u2018Inverse Neuroleptic\u2019 metoclopramide in Tourette syndrome: an open case series. J Child Adolesc Psychopharmacol. 2004;14(1):123\u20138.","journal-title":"J Child Adolesc Psychopharmacol."},{"issue":"7","key":"486_CR84","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1097\/01.chi.0000163279.39598.44","volume":"44","author":"R Nicolson","year":"2005","unstructured":"Nicolson R, Craven-Thuss B, Smith J, McKinlay BD, Castellanos FX. A randomized, double-blind, placebo-controlled trial of metoclopramide for the treatment of Tourette\u2019s disorder. J Am Acad Child Adolesc Psychiatry. 2005;44(7):640\u20136.","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"key":"486_CR85","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.neuron.2017.06.010","volume":"94","author":"AY Huang","year":"2017","unstructured":"Huang AY, Yu D, Davis LK, Sul JH, Tsetsos F, Ramensky V, Zelaya I, Ramos EM, Osiecki L, Chen JA, McGrath LM, Illmann C, Sandor P, Barr CL, Grados M, Singer HS, N\u00f6then MM, Hebebrand J, King RA, Dion Y, Rouleau G, Budman CL, Depienne C, Worbe Y, Hartmann A, M\u00fcller-Vahl KR, Stuhrmann M, Aschauer H, Stamenkovic M, Schloegelhofer M, Konstantinidis A, Lyon GJ, McMahon WM, Barta C, Tarnok Z, Nagy P, Batterson JR, Rizzo R, Cath DC, Wolanczyk T, Berlin C, Malaty IA, Okun MS, Woods DW, Rees E, Pato CN, Pato MT, Knowles JA, Posthuma D, Pauls DL, Cox NJ, Neale BM, Freimer NB, Paschou P, Mathews CA, Scharf JM, Coppola G, Tourette Syndrome Association International Consortium for Genetics (TSAICG), Gilles de la Tourette Syndrome GWAS Replication Initiative (GGRI). Rare copy number variants in NRXN1 and CNTN6 increase risk for Tourette syndrome. Neuron. 2017;94:1101\u201311.","journal-title":"Neuron."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-017-0486-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-017-0486-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-017-0486-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T23:15:25Z","timestamp":1693437325000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-017-0486-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["486"],"URL":"https:\/\/doi.org\/10.1007\/s40263-017-0486-0","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"15 January 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The funding for this publication and paying the fee for this publication to be made open access is from internal research funding granted to Keith A. Coffman, M.D. from the Department of Pediatrics at Children\u2019s Mercy Hospital, Kansas City.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Julio F. Quezada, MD, has no conflicts to report. Keith A. Coffman, MD, is the Co-Chair of the Tourette Association of America Medical Advisory Board. He has also received honoraria for lectures given on behalf of the Tourette Association of America, but the content of those lectures is original and not reviewed or edited by the Tourette Association of America. Dr. Coffman has been a site Primary Investigator for a multi-center, randomized, placebo-controlled crossover trial of ecopipam for the treatment of Tourette syndrome, sponsored by Psyadon Pharmaceuticals, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}